Navigation Links
Roche Announces Long-Term Commitment to Tackle Growing Epidemic of Diabetes
Date:5/12/2009

Roche announces wide array of ACCU-CHEK programs centered around Behavior Change through Patient Engagement (SM), including tools for better self-care.

INDIANAPOLIS, May 12 /PRNewswire/ -- Roche, the maker of ACCU-CHEK blood glucose monitoring systems and insulin pumps, announced today its long-term commitment to tackle the growing epidemic of diabetes by its Behavior Change through Patient Engagement (SM) program - a wide array of educational programs and tools that promote more effective self-care.

"As the world leader in diabetes diagnostics, we have a responsibility to provide solutions that overcome a critical gap in diabetes management," said Head of Roche Diabetes Care North America Luc Vierstraete. "Traditional diabetes management tends to focus on telling people with diabetes what to do but that, by itself, doesn't necessarily fully engage patients. Our initiative, Behavior Change through Patient Engagement, is all about helping patients take an active role in their diabetes self-care. We know that keeping patients engaged and focused on self-care is critical to long-term success and better outcomes. We are so committed to this effort, we have already invested more than $14 million toward this initiative and will continue to do so."

Roche's Behavior Change through Patient Engagement program offers:

  • Coaching skills for healthcare professionals to help achieve breakthroughs in engagement of patients;
  • Free patient education programs to help adults, children and teens make self-management easier; and
  • Easy tools that help patients discover that the actions they take every day matters - understanding how things like changes in therapy, foods or activities affect their blood glucose.

"Diabetes is a difficult, frustrating disease," said Roche Diabetes Care Medical Director Dr. Andreas Stuhr. "Our Behavior Change program helps healthcare professionals address things like diabetes burnout and other psychological barriers to effective self-care. In addition, we have devised unique and powerful tools to help patients discover that change is worthwhile and achievable."

New educational programs and tools within the Behavior Change through Patient Engagement will continue to be rolled out throughout the year. Meanwhile, existing programs have been further enhanced to fully complement the Behavior Change program.

"We are confident that, together, we can change the future of people who have diabetes," Vierstraete added. "That core belief - that behavior change is worthwhile and achievable - is essential and Roche is committed to helping provide the foundation needed for lasting change."

About Roche Diabetes Care

Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients' condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management - from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems.

For more information, please visit accu-chek.com.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R & D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche-diagnostics.us.

All trademarks used or mentioned in this release are protected by law.

    For further information, please contact:
    Julie Vincent
    Public Relations Manager
    ACCU-CHEK(R) Brand
    julie.vincent@roche.com
    317-521-1910


'/>"/>
SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis R&D Productivity Panels Also Used By Roche
2. Roche Madison Moves to New Facility
3. BioDuro and Roche Expand Strategic Collaboration to Provide Drug Discovery Services
4. Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU
5. Roche Completes Tender Offer for Genentech
6. Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation
7. SD Canada Announces CE Mark for ThyroChek(R) Adult and NeoNatal Tests
8. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
9. Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash
10. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
11. Roche Purchases Shares in Tender Offer For Memory Pharmaceuticals Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... research tools, announced the acquisition of GenWay Biotech ... a comprehensive service and product offering for both ... acquisition will facilitate growth and enhance capabilities for ... antibodies, and ELISA assays will nicely complement ASB,s ...
(Date:2/23/2017)... ... February 22, 2017 , ... Seventy-one members ... named Fellows of the Society this year, the Fellows Committee has announced. The ... of optics, photonics, and imaging as well as their service to the Society ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... Kendall Research Systems, LLC (KRS) clinical development program. KRS is a ... technology for research and clinical applications. The terms of the transaction were not ...
(Date:2/22/2017)...  PrimeVax Immuno-Oncology, Inc. announced today its CEO, ... Biocom Global Life Science Partnering Conference.  The presentation will ... the Torrey Pines Lodge, in San Diego.  ... who have chosen our company, amongst numerous others, to ... and clinical researchers," said Mr. Chen. "In contrast to ...
Breaking Biology Technology:
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis zum Jahr 2018 ... mehr als 50 Vertretern aus verschiedenen Branchen wurde aber klar, ... Prognose zu realisieren. ... Zu den Schwierigkeiten für Biobanking-Profis ... die Biobank, die Implementierung Zeit sparender Technologien, ein besseres ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
Breaking Biology News(10 mins):